NASDAQ:RGNXRegenxbio Stock Price, Forecast & News

Regenxbio's stock was trading at $32.89 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, RGNX shares have increased by 17.5% and is now trading at $38.65. View which stocks have been most impacted by Coronavirus.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Regenxbio in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Regenxbio.

Regenxbio is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Regenxbio.

Regenxbio Inc (NASDAQ:RGNX) posted its quarterly earnings results on Thursday, May, 7th. The biotechnology company reported ($1.08) EPS for the quarter, missing analysts' consensus estimates of ($0.87) by $0.21. The biotechnology company had revenue of $17.60 million for the quarter, compared to analysts' expectations of $17.99 million. Regenxbio had a negative return on equity of 27.84% and a negative net margin of 197.23%. The company's revenue for the quarter was up 1855.6% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.89) earnings per share. View Regenxbio's earnings history.

6 analysts have issued 1-year target prices for Regenxbio's shares. Their forecasts range from $37.00 to $150.00. On average, they expect Regenxbio's share price to reach $68.33 in the next twelve months. This suggests a possible upside of 76.8% from the stock's current price. View analysts' price targets for Regenxbio.

Media headlines about RGNX stock have been trending somewhat positive on Wednesday, InfoTrie Sentiment reports. InfoTrie scores the sentiment of press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Regenxbio earned a news impact score of 0.7 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the stock's share price in the next several days. View the latest news about Regenxbio.

Some companies that are related to Regenxbio include Adaptive Biotechnologies (ADPT), Acceleron Pharma (XLRN), Allogene Therapeutics (ALLO), Spark Therapeutics (ONCE), China Biologic Products (CBPO), Momenta Pharmaceuticals (MNTA), Halozyme Therapeutics (HALO), Iovance Biotherapeutics (IOVA), Ablynx (ABLYF), bluebird bio (BLUE), Denali Therapeutics (DNLI), Fate Therapeutics (FATE), Twist Bioscience (TWST), Immunovant (IMVT) and Editas Medicine (EDIT). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Regenxbio investors own include NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Voyager Therapeutics (VYGR), Crispr Therapeutics (CRSP), Gilead Sciences (GILD), Amarin (AMRN), QUALCOMM (QCOM), Bristol-Myers Squibb (BMY) and Square (SQ).

Regenxbio trades on the NASDAQ under the ticker symbol "RGNX."

Regenxbio's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Exane Derivatives (0.01%). Company insiders that own Regenxbio stock include Curran Simpson, Donald J Hayden Jr, Kenneth T Mills, Luke M Beshar, Olivier Danos, Patrick J Christmas, Stephen Yoo and Vittal Vasista. View institutional ownership trends for Regenxbio.

RGNX stock was purchased by a variety of institutional investors in the last quarter, including Exane Derivatives. View insider buying and selling activity for Regenxbio.

Shares of RGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of RGNX stock can currently be purchased for approximately $38.65.

Regenxbio has a market capitalization of $1.44 billion and generates $35.23 million in revenue each year. The biotechnology company earns $-94,730,000.00 in net income (profit) each year or ($3.26) on an earnings per share basis. Regenxbio employs 192 workers across the globe.

The official website for Regenxbio is www.regenxbio.com.

Regenxbio's mailing address is 9600 BLACKWELL ROAD SUITE 210, ROCKVILLE MD, 20850. The biotechnology company can be reached via phone at 240-552-8181 or via email at [email protected]